In new data from the OPERETTA 1 study (NCT04075266), a study of pediatric patients with relapsing-remitting multiple sclerosis (RRMS), ocrelizumab (Ocrevus; Genentech) demonstrated a safety and pharmacokinetic/pharmacodynamic (PK/PD) profile that was similar to that seen in adult patients with the disease. All told, the data identified optimal dosing ranges that will be further evaluated in the phase 3 OPERETTA 2 trial (NCT05123703), which is actively recruiting.
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045